Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New imaging test could spare thyroid cancer patients unnecessary radiation

NCT ID NCT01704586

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether using I-124 PET/CT scans can help doctors decide which thyroid cancer patients truly need radioiodine ablation therapy. About 340 adults with newly diagnosed differentiated thyroid cancer will be assigned to either standard care or I-124-guided care. The goal is to see if the imaging approach can safely reduce unnecessary radiation exposure and improve quality of life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Radioiodine I-131 and I-124
What this could lead to
If successful, this approach could reduce unnecessary radiation exposure and improve quality of life for low-risk thyroid cancer patients by personalizing treatment decisions.
What could go wrong
This is an observational study without randomization, so results may not be definitive. The long-term benefits and risks compared to standard care remain uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 340 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2015

Expected to finish

May 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria common for all study subjects prior to randomisation: * Histologically confirmed new diagnosis of DTC (including Hürthle-cell carcinoma) * Age 18-80 years * Performance Status of 0-2 * Tumor stage T1b to T4 with the possibility of lymph node involvement and distant metastasis according to the \[TNM\] staging system * One- or two stage thyroidectomy, with or without central lymph node dissection * Patient´s written informed consent * Ability to comply with the protocol procedures Exclusion criteria for all study subjects prior to randomisation: * Anaplastic or medullary carcinoma * History of prior malignancy within the past 5 years with limited life-time expectancy, except for cured non-melanoma skin cancer, cured in situ cervical carcinoma, or other treated malignancies with no evidence of disease for at least three years. * Positive pregnancy test or breast feeding * Any other severe acute or chronic medical or psychiatric condition, or laboratory abnormality that would impart, in the judgment of the investigator, excess risk associated with study participation, or which, in the judgment of the investigator, would make the patient inappropriate for entry into this study. * Recent iodine contamination After Randomisation I-124 arm: A: Inclusion criteria for no remnant ablation (low risk DTC): * Stage I (according to AJCC, ref. 1,33) papillary or follicular carcinoma with the possibility of lymph node involvement but no distant metastasis and no microscopical residual disease (Patient age \<45y: any T, any N, M0; Patient age 45y or older: T1, N0, M0) * I-124 uptake only in thyroid bed * Absence of aggressive malignant histologic subtypes, including tall-cell, insular, poorly differentiated and diffuse sclerosing thyroid cancer B: Inclusion criteria for remnant ablation (high risk DTC): * All other \[TNM\] stages (stage II to stage IV C) * Presence of aggressive malignant histologic subtypes, including tall-cell, insular, poorly differentiated and diffuse sclerosing thyroid cancer * I-124 uptake in and outside thyroid bed Standard arm: -Standard I-131 ablation concept as defined for all T1b to T4 subjects.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Differentiated thyroid carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Clinic of Nuclear Medicine, University Clinic Essen

    Essen, 45122, Germany

  • University Clinic Würzburg

    Würzburg, 97080, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.